As an analyst for Datamonitor Healthcare’s Oncology team, Michael delivers astute, top-quality, quantitative insights and consultation regarding the dynamics of oncology products in the pharmaceutical industry. He has produced reports on treatment trends, marketed and pipeline drugs, as well as market forecasts and opinion pieces on several oncological malignancies.
Michael joined Datamonitor Healthcare in 2017 after performing research on non-small cell lung cancer and small cell lung cancer as a graduate student and postdoctoral researcher. He now leverages this scientific background towards analysis of the next generation of oncology treatments and their impact on the existing market. One of the highlights of his role has been developing in-depth forecasts that provide context and actionable insights for clients.
He has a B.S. in Human Biology from the University of California, San Diego, and a Ph.D. in Cancer Biology from the University of Texas Southwestern Medical Center.